Logan Coy Related postsA Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer After Prior ChemotherapySeptember 11, 2026A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin with Lenalidomide and Dexamethasone (BRd) vs Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Newly Diagnosed Multiple Myeloma Ineligible for Autologous Stem Cell Transplantation (DREAMM-10)September 11, 2026A Phase 3, Randomized, Double-blind, Add-on Study of Navtemadlin plus Ruxolitinib vs Placebo plus Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis with Suboptimal Response to RuxolitinibSeptember 11, 2026 Previous postA Phase 3, randomised, double-blind, placebo-controlled, multicentre trial comparing trilaciclib versus placebo in limited-stage small cell lung cancerNext postA Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study of Belantamab as Monotherapy and in Combination with Other Treatments in Multiple Myeloma